Table 2 Associations of the patient characteristics with the OS (log-rank test)
OS (median) | 95% CI | P | ||
|---|---|---|---|---|
Age (years) | <75 | 40.0 | 31.5–NE | 0.523 |
≥75 | 34.0 | 25.5–52.7 | ||
Sex | Male | 33.1 | 20.5–46.8 | 0.254 |
Female | 52.7 | 30.4–NE | ||
Histology | Adenocarcinoma | 40.0 | 31.5–54.7 | 0.931 |
Others | 32.3 | 22.6–32.3 | ||
EGFR mutation | Exon 19 del | NR | 33.1–NE | 0.011 |
Exon 21 L858R | 40.0 | 22.6–52.7 | ||
Uncommon mutation | 32.3 | 5.3–NE | ||
PS | 0–1 | 52.7 | 34.0–87.6 | 0.002 |
≥2 | 30.4 | 10.3–40.0 | ||
LDH (U/L) | <200 | 51.3 | 34.0–78.5 | 0.046 |
≥200 | 28.6 | 17.2–NE | ||
PD-L1 TPS | ≥1% | 51.3 | 32.3–87.6 | 0.394 |
<1% | 46.8 | 30.4–78.5 | ||
Unknown | 31.5 | 19.4–NE | ||
History of surgery | Yes | NR | 28.3–NE | 0.184 |
No | 38.8 | 28.6–52.7 | ||
Brain metastasis | Yes (with local therapy) | NR | 36.1–NE | 0.033 |
Yes (without local therapy) | 17.2 | 5.3–NE | ||
No | 34.0 | 28.6–52.7 | ||
First-line TKI used | 1st-generation TKIs | 36.1 | 28.0–51.3 | 0.157 |
Afatinib | NR | 19.2–NE | ||
Osimertinib | NR | 20.5–NE | ||
History of platinum-doublet therapy | Yes | 40.3 | 28.6–NE | 0.470 |
No | 34.0 | 28.3–87.6 | ||
History of VEGF inhibitor therapy | Yes | 54.7 | 11.0–54.7 | 0.895 |
No | 38.8 | 30.4–78.5 | ||
Sequential therapy with TKIs | Osimertinib | 78.5 | 46.8–NE | 0.019 |
1st/2nd-generation TKIs | 31.5 | 13.0–NE | ||
None | 33.0 | 22.6–38.8 | ||
History of ICI therapy | Yes | 54.7 | 18.7–NE | 0.389 |
No | 36.1 | 28.6–78.5 |